NSTM
NovelStem International Corp.0.0200
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
937.63KP/E (TTM)
0.40Basic EPS (TTM)
0.05Dividend Yield
0%Recent Filings
10-Q
10-Q
Q2 FY2025 results
NovelStem swung to a net profit of $2.5M for the six months ended June 30, 2025, up from a $0.6M loss last year, driven by $1.7M relief of indebtedness from settling a $3.0M litigation funding liability via the noncash sale of its 50% NetCo stake on May 9, 2025, plus a $1.2M gain on that disposal; Q2 alone delivered $2.8M income versus a $0.3M loss prior year. Operating losses narrowed to $0.2M from $0.3M y/y, with G&A expenses dropping 52% to $159K on lower legal and audit costs, while interest expense fell 19% to $164K after the settlement. Cash dipped to $1.1K amid $110K operating burn, offset by $106K in related-party bridge loans; total debt stands at $1.6M, mostly short-term notes at 10-12% maturing late 2025. Diluted EPS of $0.05 reconciles cleanly to 47.8M shares. Yet liquidity strains persist.
10-Q
Q1 FY2025 results
NovelStem International Corp. posted a narrower net loss of $207,216 for Q1 2025 ended March 31, versus $303,280 a year earlier, as administrative fee income dried up to zero from $3,000 while G&A expenses dropped 48% to $94,574 on lower professional fees. Operating loss improved to $(94,574) from $(180,306), but interest expense climbed 19% to $112,642 amid rising debt; net loss exceeded operating by $113,068, mainly from interest. Cash dwindled to $3,401 from $6,099, with operating cash use at $43,698 offset by $41,000 in bridge financing from the executive chairman. Total debt hit $4,601,611 including accrued interest, all current with no revolver. Post-quarter, on May 9, 2025, the company sold its 50% NetCo stake for $1,300,000 to settle a $3,000,000 litigation funding liability in full. Non-GAAP metrics not disclosed in the 10-Q. Yet liquidity strains persist.
10-K
FY2024 results
NovelStem International Corp. narrowed its net loss to $3.2 million in FY2024 from $4.2 million the prior year, driven by a sharp drop in litigation expenses to $59,000 from $2.9 million as the NetCo arbitration wrapped up, though an impairment charge wiped out its $1.6 million investment in NewStem after the biotech unit ceased operations in Q4 and entered liquidation. Administrative fee income held steady at $12,000 annually, while G&A costs rose 32% to $881,000 amid bad debt write-offs on $500,000 in NewStem loans and higher professional fees. Q4 momentum stalled with NewStem's shutdown, but the company advanced $250,000 in Q4 loans that proved uncollectible, underscoring liquidity strains with cash dipping to $6,000 from $53,000. Debt ballooned to $5.3 million, including $4.1 million in notes with related parties, yet a pending NetCo sale for $1.3 million could settle litigation funding obligations. No dividends or buybacks occurred. Illiquid holdings in NetCo and NewStem's reverted tech pose ongoing risks to quarterly cash flows.
10-Q
Q3 FY2024 results
NovelStem International Corp. posted a net loss of $3.1M for the nine months ended September 30, 2024, improved from $4.2M a year earlier, driven by the absence of prior-year litigation costs yet offset by a $1.6M impairment on its NewStem investment amid the biotech's liquidation. Administrative fee income held steady at $9,000 year-over-year, while G&A expenses climbed 40.7% to $894K, fueled by a $500K bad debt write-off on NewStem advances; operating loss narrowed to $885K from $3.4M. Q3 alone saw a $2.5M net loss, up from $1.1M last year, with EPS at $(0.05) on 46.9M diluted shares, consistent across periods. Cash dipped to $45K from $53K at year-start, with $233K used in operations and $475K raised via related-party notes and convertible debt; total debt stood at $4.1M, including a $2.9M litigation funding liability due January 2025. No free cash flow disclosed in the 10-Q. The arbitration win affirmed rights to exploit NetCo's Net Force IP, but joint venture control remains contested.
ACUT
Accustem Sciences Inc.
0.70-0.05
BSEM
BioStem Technologies, Inc.
3.84-0.11
CHEK
Check-Cap Ltd.
1.61+0.03
ISCO
International Stem Cell Corp.
0.14-0.03
NEO
NeoGenomics, Inc.
11.67-0.25
NGHI
New Green Hemp Inc.
0.30+0.00
NOTV
Inotiv, Inc.
0.68-0.02
NVCR
NovoCure Limited
12.93-0.04
RMTG
Regenerative Medical Technology
0.04+0.00
STEK
Stemtech Corp.
0.00-0.00